Vaccines Alliance Gets New CEO
A key Geneva-based public-private initiative to increase global vaccination has named a new CEO.
Original news and analysis on international IP policy
A key Geneva-based public-private initiative to increase global vaccination has named a new CEO.
The newly created Medicines Patent Pool promises to increase access to HIV/AIDS medications in developing markets. Based in Geneva, Switzerland, the pool operates a scheme in which pharmaceutical patent holders voluntarily licence their drugs to generic manufacturers who then produce more affordable versions for patients in poorer countries
US President Obama today nominated current US Commerce Secretary Gary Locke to be ambassador to China. US intellectual property rights holders see it as a positive contribution to what they see as a fight against massive piracy and counterfeiting from China.
Free Press, a US non-profit working to reform media, announced that its president is stepping down after almost a decade, to be replaced by the current managing director in mid-April.
A number of law firms and a key trademark industry group have made changes in recent weeks aimed at boosting their intellectual property practices.
The Free Software Foundation (FSF) has announced the appointment of a new executive director.
The new international agreement on access and benefit-sharing of genetic resources has many IP implications, according to panellists at an event last week. And at least one United Nations agency is launching an effort to help countries with those IP implications.

Benny Spiewak writes: There used to be a time when Brazil meant almost exclusively Carnival, Samba and Soccer. Well, those days are over and there is an undeniable message that will echo through the knowledge-based, creative, innovative world: Wake-Up, World, It’s Tropicalization Time!
The Motion Picture Association of America, the influential US film industry group, has landed a highly regarded former US senator as its next chairman and chief executive officer.
On the eve of a meeting of the WHO working group on substandard/spurious/falsely-labelled/falsified/counterfeit medical products, research-based pharmaceutical industry group IFPMA sets out thoughts on building global consensus to address fake medicines.
A Washington intellectual property lawyer and private sector representative has been named deputy director at the United States Patent and Trademark Office. Her area of expertise is pharmaceutical, biotechnology and other life science issues.
A recent decision issued by Advocacia-Geral da União (Advocacy-General of the Union) restricts the role performed by Anvisa - the National Agency for Health Surveillance - in examining pharmaceutical patent applications. This may represent a huge setback for commitments made by Brazilian government related to the protection of public health, writes Felipe Carvalho.